JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

Size: px
Start display at page:

Download "JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study"

Transcription

1 Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary Objectives Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin To investigate whether rosuvastatin 20 mg compared to placebo would decrease the rate of first major cardiovascular events among apparently healthy men and women with LDL < 130 mg/dl (3.36 mmol/l) who are nonetheless at increased vascular risk on the basis of an enhanced inflammatory response, as determined by hscrp > 2 mg/l. To enroll large numbers of women and individuals of Black or Hispanic ethnicity, groups for whom little data on primary prevention with statin therapy exists. The Trial: Will You Change Your Practice? In patients with hyperlipidemia, treatment with statins reduces cardiovascular risk, even in people without a history of cardiovascular disease. However, nearly half of all first cardiovascular events occur in people whose low-density lipoprotein (LDL) cholesterol levels are below current thresholds for lipid-lowering therapy. Therefore, recent research has sought to refine our ability to identify people who are at risk and to find interventions capable of reducing that risk. NEJM Poll Do you believe, on the basis of the trial results, that the approach to laboratory screening of apparently healthy adults should be changed? Yes, the trial results indicate that the approach to laboratory screening should be changed. 49% No, the trial results do not provide a basis for a change in the approach to laboratory screening. 51% 2553 total responses

2 NEJM Poll Do you believe, on the basis of the trial results, that the therapeutic use of statins in apparently healthy adults should be changed? LDLC Levels in 136,905 Patients Hospitalized With CAD: LDLC (mg/dl) < > 160 Yes, the trial results indicate that the therapeutic use of statins should be changed. 48% No, the trial results do not provide a basis for a change in the therapeutic use of statins. 52% Sachdeva et al, Am Heart J 2009;157:111-7.e2. CTT meta-analysis: Proportional reduction in NON-FATAL MI or CHD DEATH versus absolute LDL-C reduction The Acute-Phase Response Pathway Proportional reduction in coronary event rate (95% CI) 30% 25% 20% 15% 10% 5% 0% A to Z IDEAL SEARCH TNT PROVE-IT More vs less (5 trials) Statin vs control (18 trials) Proinflammatory Risk Factors Primary Proinflammatory Cytokines (eg, IL-1, TNF-a) ICAM-1 Selectins, HSPs, etc. Endothelium and other cells Circulation IL-6 Messenger Cytokine CRP SAA Liver Mean LDL cholesterol difference between treatment groups (mmol/l) Adapted from Libby, Ridker. Circulation ;100:

3 CRP Epidemiology Is C-reactive protein (CRP) a causal factor in the pathogenesis of atherosclerosis? If it is, implications could be far reaching for new approaches for the prevention and treatment of myocardial infarction and stroke. CRP Epidemiology Support for a role of CRP in the pathogenesis of atherosclerosis are from epidemiologic studies that have consistently observed an association between elevated plasma CRP levels and cardiovascular events. CRP: Chicken or the EGG? Why Consider Statins for Low LDL, high hscrp Patients? AFCAPS/TexCAPS Low LDL Subgroups Low Low LDL, LDL, Low LowhsCRP Low Low LDL, LDL, High HighhsCRP hscrp [A] [B] Statin Statin Effective Effective RR Statin Statin Not Not Effective Effective However, while intriguing and of potential public health importance, the observation in AFCAPS/TexCAPS that statin therapy might be effective among those with elevated hscrp but low cholesterol was made on a post hoc basis. Thus, a large-scale randomized trial of statin therapy was needed to directly test this hypotheses. Ridker et al, New Engl J Med 2001;344:

4 Trial Design Multi-National Randomized Double Blind Placebo Controlled Trial of Rosuvastatin in the Prevention of Cardiovascular Events Among Individuals With Low LDL and Elevated hscrp No Prior CVD or DM Men >50, Women >60 LDL <130 mg/dl hscrp >2 mg/l 4-week run-in Ridker et al, NEJM : MI Rosuvastatin 20 mg (N=8901) Stroke Unstable Angina Placebo (N=8901) CVD Death CABG/PTCA Baseline LDLC Baseline HDLC Baseline hscrp 104 mg/dl 49 mg/dl 4.2 mg/l Women 6,800 Non-Caucasian 5,000 Baseline Clinical Characteristics Rosuvastatin Placebo (N = 8901) (n = 8901) Age, years (IQR) 66.0 ( ) 66.0 ( ) Female, N (%) 3,426 (38.5) 3,375 (37.9) Ethnicity, N (%) Caucasian 6,358 (71.4) 6,325 (71.1) Black 1,100 (12.4) 1,124 (12.6) Hispanic 1,121 (12.6) 1,140 (12.8) Blood pressure, mm (IQR) Systolic 134 ( ) 134 ( ) Diastolic 80 (75-87) 80 (75-87) Smoker, N (%) 1,400 (15.7) 1,420 (16.0) Family History, N (%) 997 (11.2) 1,048 (11.8) Metabolic Syndrome, N (%) 3,652 (41.0) 3,723 (41.8) Aspirin Use, N (%) 1,481 (16.6) 1,477 (16.6) All values are median (interquartile range) or N (%) Baseline Blood Levels (median, interquartile range) Effects of rosuvastatin 20 mg on LDL, HDL, TG, and hscrp Rosuvastatin Placebo (N = 8901) (n = 8901) hscrp, mg/l 4.2 ( ) 4.3 ( ) LDL, mg/dl 108 (94-119) 108 (94-119) HDL, mg/dl 49 (40 60) 49 (40 60) Triglycerides, mg/l 118 (85-169) 118 (86-169) 50% 12-months LDL reduction 4% 12-months HDL increase Total Cholesterol, mg/dl 186 ( ) 185 ( ) Glucose, mg/dl 94 (87 102) 94 (88 102) HbA1c, % 5.7 ( ) 5.7 ( ) All values are median (interquartile range). [ Mean LDL = 104 mg/dl ] 37% 12-months hs CRP 37% reduction Months 17% 12-months TG 17% reduction Months

5 - Primary Endpoint Time to first occurrence of a CV death, non-fatal stroke, non-fatalmi, unstable angina or arterial revascularization Cumulative Incidence Hazard Ratio 0.56 (95% CI ) P< Placebo - 44 % Rosuvastatin 20 mg NNT for 2y = 95 5y* = Number at Risk Follow-up (years) Rosuvastatin 8,901 8,631 8,412 6,540 3,893 1,958 1, Placebo 8,901 8,621 8,353 6,508 3,872 1,963 1, *Extrapolated figure based on Altman and Andersen method Ridker P et al. N Eng J Med 2008;359: Predicted Benefit Based on LDL Reduction vs Observed Benefit Proportional reduction in vascular event rate (95% CI) A-to-Z TNT IDEAL CTT PROVE-IT Mean LDL cholesterol difference between treatment groups (mmol/l) PREDICTED Predicted Benefit Based on LDL Reduction vs Observed Benefit Primary Endpoint Subgroup Analysis II 55 N P for Interaction Proportional reduction in vascular event rate (95% CI) A-to-Z TNT IDEAL Mean LDL cholesterol difference between treatment groups (mmol/l) CTT PROVE-IT OBSERVED PREDICTED Family HX of CHD No Family HX of CHD BMI < 25 kg/m 2 2 BMI kg/m 2 BMI >30 kg/m Metabolic Syndrome No Metabolic Syndrome Framingham Risk < 10% Framingham Risk > 10% hscrp > 2 mg/l Only All Participants 2, ,684 4,073 37% 0.70 PCR reduction 7,009 6,675 hscrp > 2 mg/l Only 6,375 REVERSAL 7, ,296 8, ,895 6,375 17,802 in. Same magnitude in Rosuvastatin Superior Rosuvastatin Inferior

6 . Primary End Point NNT (1 event): 120 patients treated for 1.9 years Ridker P et al. N Eng J Med 2008;359: Primary Prevention with Statins : Caveats Benefits vs Adverse Events NNH=166. That means: More than a new-onset diabetes vs 2 prevented events Primary Prevention with Statins : Caveats. Study Stopped Earlier than planned Lipids an IHD Secondary Prevention Y=0,1629x-4,6776 R 2 =0,9029 P<0,0001 4S-P Overestimate the beneficial effects MACE (%) 20 HPS-S 4S-S LIPID-P 15 HPS-S CARE-P LIPID-S 10 PROVE-IT- CARE-S AT SPARCL-P PROVE-IT 5 PR SPARCL-A LDL-C (mg/dl) O Keefe, Jr et al J Am Col Cardiol 2004;43:2142-6

7 A Comparative Study of Biomarkers in Acute Coronary Syndrome Results of the SIESTA study Biomarker levels (categorized in thirds) and the occurrence of the 360-day second study endpoint 1 No events 556 (91.1%) Events 54 (8.9%) P Variable (median) 1st third, n (%) 189 (34) 15 (27.8) CRP, mg/l 2nd third, n (%) 188 (33.8) 15 (28.8) rd third, n (%) 179 (32.2) 24 (44.4) Statins in Primary Prevention Estimation of additional number to treat in U.S. with the selection criteria of 1st third, n (%) 154 (34.9) 7 (17.5) NT-ProBNP, ng/l 2nd third, n (%) 147 (33.3) 13 (32.5) rd third, n (%) 140 (31.7) 20 (50) 1st third, n (%) 183 (34.9) 12 (24) Cystatin C, mg/l 2nd third, n (%) 178 (34) 16 (32) rd third, n (%) 163 (31.1) 22 (44) 1st third, n (%) 183 (35) 6 (12) Fibrinogen, mg/dl 2nd third, n (%) 171 (32.7) 18 (36) rd third, n (%) 169 (32.3) 26 (52) 1 Second composite endpoint represents the occurrence of new non-fatal acute myocardial infarction or all-cause death Kaski JC et al. JACC 2009 Circ Cardiovasc Qual Outcomes 2009;2:41-48 Jupiter Study Limitations The study did not include anyone with hscrp < 2.0 mg/l and therefore the trial does not inform whether people with normal, low, or no hscrp values would have also benefited from the robust LDL-C C lowering. So the ultimate value of hscrp for selecting patients for treatment remains unknown. Principal investigator disclosed financial conflicts of interest as a co-inventor on patents that relate to the use of hscrp in the evaluation of patients risk of cardiovascular disease. AstraZeneca, manufacturer of rosuvastatin, sponsored the study.. Clinical Implications: Is justified treat with statins a population () with normal LDL-cholesterol? Subgroups? YES Whom? Based on Global CV Risk Is necesary a population screening? NO Are these results extrapolable to other statins? Possibly NO

8 THE TRIAL A Consensus Statement for KP Health Care Providers from the Dyslipidemia Management Guideline Development Team Our first priority is to initiate statins and ensure adherence among our high risk members with coronary artery disease, diabetes or coronary artery disease risk equivalents. hscrp has no role in these therapy decisions and should not be ordered. FHS: Risk Assessment Tool for Estimating 10- year Risk of Developing Hard CHD (Myocardial Infarction and Coronary Death) Framingham Heart Study to estimate 10-year risk for hard coronary heart disease outcomes (myocardial infarction and coronary death). This tool is designed to estimate risk in adults aged 20 and older who do not have heart disease or diabetes. 1. Age: years 2. Gender: Female Male 3. Total Cholesterol: mg/dl 4. HDL Cholesterol: mg/dl 5. Smoker: No, Yes 6. Systolic Blood Pressure: mm/hg 7. Currently on medication to treat high blood pressure. No, Yes THE TRIAL A Consensus Statement for KP Health Care Providers from the Dyslipidemia Management Guideline Development Team Recommendations Apply ONLY to Patients for Primary Prevention 1. Do not measure hscrp if decision for Rx already made 2. Determine Framingham 10-year risk status. For people at > 20% risk: If baseline LDL-C C is mg/dl initiate simvastatin 40 mg daily. If baseline LDL-C C is > 160 mg/dl initiate simvastatin 80 mg daily. If baseline LDL-C C is < 100 mg/dl, it is optional to measure hscrp in men > 50 years old and women > 60 years old, and if hscrp is > 2 mg/l, to initiate simvastatin 40 mg daily. (not fully EBM) Target LDL-C C is < 100 mg/dl. THE TRIAL A Consensus Statement for KP Health Care Providers from the Dyslipidemia Management Guideline Development Team For people at Framingham 10-20% risk: If baseline LDL-C C is mg/dl, initiate simvastatin 40 mg daily. If baseline LDL-C C is > 220 mg/dl, initiate simvastatin 80 mg daily. If baseline LDL-C C is < 130 mg/dl, it is optional to measure hscrp in men > 50 years old and women > 60 years old, and if hscrp is > 2 mg/l, to initiate simvastatin 40 mg daily. (not fully EBM) Target LDL-C C is < 130 mg/dl.

9 THE TRIAL A Consensus Statement for KP Health Care Providers from the Dyslipidemia Management Guideline Development Team For people at <10% risk: If baseline LDL-C is mg/dl, initiate simvastatin 40 mg daily. If baseline LDL-C is > 220 mg/dl, initiate simvastatin 80 mg daily. If baseline LDL-C is < 190 mg/dl, it is optional to measure hscrp in men > 50 years old and women > 60 years old, and if hscrp is > 2 mg/l, to initiate simvastatin 40 mg daily. (not fully EBM) Target LDL-C is <130 mg/dl. Caveats of CRP Measurement Do not use hscrp to monitor therapy. Information Regarding hscrp Ordering and Interpretation hscrp should be ordered only in metabolically stable patients who are free of active infection, systemic inflammation*, recent trauma and are not on estrogen therapy, immunosuppressants or glucocorticoids. If hscrp is > 2 mg/l, repeat hscrp two weeks later. Statin therapy contingent on hscrp is only recommended if two hscrp tests are both > 2 mg/l. If hscrp is > 10 mg/l, the patient should be evaluated for sources of infection or inflammation and the test repeated. The standard CRP test is not useful for cardiac risk assessment and should not be ordered for this purpose. The correct test is the highsensitivity CRP, sometimes called the cardio CRP or wide range CRP.

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain

More information

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular

More information

Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)

Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Stable CAD (post MI) On Statin, ACE/ARB, BB, ASA Persistent Elevation of hscrp (> 2 mg/l) N = 10,061 39 Countries April 2011 - June 2017

More information

New Insights into the Biology of Atherosclerosis and Primary Prevention: Controversy and Consensus in the JUPITER Trial

New Insights into the Biology of Atherosclerosis and Primary Prevention: Controversy and Consensus in the JUPITER Trial Fundacion Fernandez-CruzXXVIII Leccion Memorial New Insights into the Biology of Atherosclerosis and Primary Prevention: Controversy and Consensus in the JUPITER Trial Paul M Ridker, MD, MPH Eugene Braunwald

More information

Expert Meeting on Large Simple Trials (LST s)

Expert Meeting on Large Simple Trials (LST s) Expert Meeting on Large Simple Trials (LST s) Clinical Trials Transformation Initiative Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin JUPITER Johannes

More information

Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) New York City Cardiovascular Symposium December 10, 2017 Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Paul M Ridker, MD, MPH

More information

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment

More information

Review of guidelines for management of dyslipidemia in diabetic patients

Review of guidelines for management of dyslipidemia in diabetic patients 2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University

More information

Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus

Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus C. Noel Bairey Merz MD, FACC, FAHA Professor and Women s Guild Endowed Chair Director, Barbra Streisand Women

More information

Dyslipidemia in women: Who should be treated and how?

Dyslipidemia in women: Who should be treated and how? Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European

More information

CRP for the Clinician

CRP for the Clinician CRP for the Clinician J. C. Kaski, D.Sc., M.D., D.M (Hons), F.E.S.C., F.R.C.P., F.A.C.C. F.A.H.A Professor of Cardiovascular Science Head, Cardiovascular Sciences Research Centre St George s, University

More information

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by

More information

The Clinical Unmet need in the patient with Diabetes and ACS

The Clinical Unmet need in the patient with Diabetes and ACS The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge

More information

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor

More information

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease

More information

journal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract

journal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract The new england journal of medicine established in 1812 november 20, 2008 vol. 359 no. 21 to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M Ridker, M.D., Eleanor Danielson,

More information

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,

More information

Preventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk

Preventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk PREVENTING CARDIOVASCULAR DISEASE WITH LIPID MANAGEMENT : MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict

More information

Is Lower Better for LDL or is there a Sweet Spot

Is Lower Better for LDL or is there a Sweet Spot Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,

More information

Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?

Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi

More information

LDL and the Benefits of Statin Therapy

LDL and the Benefits of Statin Therapy LDL and the Benefits of Statin Therapy Allan Sniderman McGill University ACC/AHA did not recommend a target-based approach. Right? P 2899 The Expert Panel was unable to find any RCTs that evaluated titration

More information

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Placebo-Controlled Statin Trials Prevention Of CVD in Women MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

LDL cholesterol and cardiovascular outcomes?

LDL cholesterol and cardiovascular outcomes? LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary

More information

Inflammation as A Target for Therapy. Focus on Residual Inflammatory Risk

Inflammation as A Target for Therapy. Focus on Residual Inflammatory Risk ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center

More information

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space? Disclosures JUPITER: The final frontier in statin utilization or an idea from outer space? Kathy E. Komperda, PharmD, BCPS Midwestern University Chicago College of Pharmacy kkompe@midwestern.edu 4/25/09

More information

New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?

New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate

More information

Introduction. Objective. Critical Questions Addressed

Introduction. Objective. Critical Questions Addressed Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:

More information

ATP IV: Predicting Guideline Updates

ATP IV: Predicting Guideline Updates Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations

More information

Rikshospitalet, University of Oslo

Rikshospitalet, University of Oslo Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular

More information

Welcome! Mark May 14, Sat!

Welcome! Mark May 14, Sat! Welcome! Mark May 14, Sat! Do We Have All Answers with Statins In Treating Patients with Hyperlipidemia? Kwang Kon Koh, MD, PhD, FACC, FAHA Cardiology, Gil Heart Center, Gachon Medical School, Incheon,

More information

The TNT Trial Is It Time to Shift Our Goals in Clinical

The TNT Trial Is It Time to Shift Our Goals in Clinical The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia

More information

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III

More information

How to Reduce Residual Risk in Primary Prevention

How to Reduce Residual Risk in Primary Prevention How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

Beyond Framingham: Risk Assessment & Treatment for Primary Prevention

Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Ronald M. Goldenberg, MD, FRCPC, FACE Consultant Endocrinologist, North York General Hospital Medical Co-Director, LMC Endocrinology

More information

Weintraub, W et al NEJM March Khot, UN et al, JAMA 2003

Weintraub, W et al NEJM March Khot, UN et al, JAMA 2003 Global risk hscrp Should not be included in a Global Cardiovascular Risk Assessment. Jodi Tinkel, MD Assistant Professor Director of Cardiac Rehabilitation Associate Program Director, Cardiovascular Medicine

More information

Hyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH

Hyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the

More information

Therapeutic Implications of Vascular Inflammation: The Cardiovascular Inflammation Reduction Trials

Therapeutic Implications of Vascular Inflammation: The Cardiovascular Inflammation Reduction Trials Therapeutic Implications of Vascular Inflammation: The Cardiovascular Inflammation Reduction Trials ESC Munich August 25, 2012 Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School

More information

The Clinical Debates

The Clinical Debates The Clinical Debates Speakers: Round 2: Statins for Primary Prevention of Cardiovascular Disease Matthew Cantrell, PharmD, BCPS, is a 2000 graduate of Mt. Mercy College and 2005 graduate from the University

More information

Landmark Clinical Trials.

Landmark Clinical Trials. Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug

More information

1. Which one of the following patients does not need to be screened for hyperlipidemia:

1. Which one of the following patients does not need to be screened for hyperlipidemia: Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:

More information

ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS

ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut Adjunct

More information

Is it an era for statin for life?

Is it an era for statin for life? Is it an era for statin for life? Mohamed Abdel Ghany Professor of Cardiology Cairo University Cardiovascular Disease (CVD) is the leading global cause of death 1 Dyslipidemia as a main Risk Factor for

More information

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy? Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists

More information

CLINICAL OUTCOME Vs SURROGATE MARKER

CLINICAL OUTCOME Vs SURROGATE MARKER CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical

More information

Sanjay Kaul, MD, FACC, FAHA Division of Cardiology Cedars-Sinai Medical Center Los Angeles, California

Sanjay Kaul, MD, FACC, FAHA Division of Cardiology Cedars-Sinai Medical Center Los Angeles, California Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay

More information

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical

More information

Best Lipid Treatments

Best Lipid Treatments Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis

More information

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories

More information

Contemporary management of Dyslipidemia

Contemporary management of Dyslipidemia Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that

More information

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

No relevant financial relationships

No relevant financial relationships MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu

More information

Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence

Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,

More information

Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice

Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP

More information

Lipid Studies That Rocked My World Gabor Gyenes Medicine Grand Rounds May 27, 2011

Lipid Studies That Rocked My World Gabor Gyenes Medicine Grand Rounds May 27, 2011 Lipid Studies That Rocked My World Gabor Gyenes Medicine Grand Rounds May 27, 2011 Disclosure of Conflicts of Interest I have received travel grants and honoraria from sanofi-aventis, Pfizer, Servier,

More information

The Framingham Coronary Heart Disease Risk Score

The Framingham Coronary Heart Disease Risk Score Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although

More information

Prospective Natural-History Study of Coronary Atherosclerosis

Prospective Natural-History Study of Coronary Atherosclerosis Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything

More information

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

Novel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy

Novel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,

More information

JAMA. 2011;305(24): Nora A. Kalagi, MSc

JAMA. 2011;305(24): Nora A. Kalagi, MSc JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for

More information

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20

More information

Environmental. Vascular / Tissue. Metabolics

Environmental. Vascular / Tissue. Metabolics Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood

More information

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial

More information

CVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure

CVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University

More information

The Diabetes Link to Heart Disease

The Diabetes Link to Heart Disease The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM

More information

Statins and endothelium function

Statins and endothelium function Statins and endothelium function Matthias Endres Berlin, Germany Klinik und Poliklinik für Neurologie Conflict of interest: research grant from AstraZeneca from prevention to acute therapy... Pleiotropic

More information

Top 5 (Topics) Papers In GIM Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008

Top 5 (Topics) Papers In GIM Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008 Top 5 (Topics) Papers In GIM 2008 Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008 Methods Searched ACPJC/EBM, TOC of top medical journals, MEDSCAPE Best Evidence, consultation

More information

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools. UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,

More information

Modern Lipid Management:

Modern Lipid Management: Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)

More information

Effective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)

Effective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA) Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular

More information

PCSK9 Inhibitors and Modulators

PCSK9 Inhibitors and Modulators PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s

More information

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,

More information

Dyslipedemia New Guidelines

Dyslipedemia New Guidelines Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy

More information

The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories

The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories Cardiac biomarkers in atherosclerosis Najma Asadi MD-APCP Ross and Colleagues in 1973: Response to Injury

More information

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies

More information

New Paradigms in Predicting CVD Risk

New Paradigms in Predicting CVD Risk New Paradigms in Predicting CVD Risk Imaging as an Integrator of Lifetime Risk Exposure Michael J. Blaha MD MPH Presented by: Michael J. Blaha September 24, 2014 1 Talk Outline Risk factors vs. Disease

More information

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for + Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics

More information

Decline in CV-Mortality

Decline in CV-Mortality Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer

More information

Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction

Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical

More information

rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.

rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

Ten Year Risk for CVD Event by Systolic HTN and CVD Risk Factors (Where s Age?)

Ten Year Risk for CVD Event by Systolic HTN and CVD Risk Factors (Where s Age?) Prevention and Treatment of CVD in Older Patients with Diabetes and Pre Diabetes: Hypertension and Dyslipidemia ASP Workshop on Diabetes Mellitus and Cardiovascular Disease in Older Adults Pentagon City

More information

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili

More information

Weigh the benefit of statin treatment: LDL & Beyond

Weigh the benefit of statin treatment: LDL & Beyond Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research

More information

Experiences with interim trial monitoring, particularly with early stopped trials

Experiences with interim trial monitoring, particularly with early stopped trials Experiences with interim trial monitoring, particularly with early stopped trials 1 Robert J Glynn, ScD Divisions of Preventive Medicine and Pharmacoepidemiology & Pharmacoeconomics, Brigham & Women s

More information

An update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine

An update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal

More information

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

More information

CHOLESTEROL-LOWERING THERAPHY

CHOLESTEROL-LOWERING THERAPHY CHOLESTEROL-LOWERING THERAPHY TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 50,194 15,036 30.0% 60.8 3.2 1/ 6 (16.7%) HR

More information

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. 2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality

More information

Lessons from Recent Atherosclerosis Trials

Lessons from Recent Atherosclerosis Trials Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD

More information

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic

More information

Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp

Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp Página 1 de 5 Return to Medscape coverage of: American Society of Hypertension 21st Annual Scientific Meeting and Exposition Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions

More information

The Atherogenic Dyslipidemia of Diabetes Mellitus- Not just a question of LDL-C

The Atherogenic Dyslipidemia of Diabetes Mellitus- Not just a question of LDL-C The Atherogenic Dyslipidemia of Diabetes Mellitus- Not just a question of LDL-C Eun-Jung Rhee Department of Endocrinology and Metabolism Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine

More information

Accelerated atherosclerosis begins years prior to the diagnosis of diabetes

Accelerated atherosclerosis begins years prior to the diagnosis of diabetes Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients

More information

Methods. Background and Objectives STRADIVARIUS

Methods. Background and Objectives STRADIVARIUS STRADIVARIUS Effect of on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease Steven E. Nissen MD Stephen J. Nicholls MBBS PhD, Kathy Wolski MPH, Josep Rodés-Cabau

More information